TY - JOUR
T1 - Bacteriophages, gut bacteria, and microbial pathways interplay in cardiometabolic health
AU - Kirk, Daniel
AU - Costeira, Ricardo
AU - Visconti, Alessia
AU - Khan Mirzaei, Mohammadali
AU - Deng, Li
AU - Valdes, Ana M
AU - Menni, Cristina
N1 - Funding Information:
C.M. and D.K. are funded by the Chronic Disease Research Foundation . Support for this work was also provided by UKRI / MRC grants MR/W026813/1 and MR/Y010175/1 to C.M. and A.M.V.
Publisher Copyright:
© 2024 The Author(s)
PY - 2024/2/27
Y1 - 2024/2/27
N2 - Cardiometabolic diseases are leading causes of mortality in Western countries. Well-established risk factors include host genetics, lifestyle, diet, and the gut microbiome. Moreover, gut bacterial communities and their activities can be altered by bacteriophages (also known simply as phages), bacteria-infecting viruses, making these biological entities key regulators of human cardiometabolic health. The manipulation of bacterial populations by phages enables the possibility of using phages in the treatment of cardiometabolic diseases through phage therapy and fecal viral transplants. First, however, a deeper understanding of the role of the phageome in cardiometabolic diseases is required. In this review, we first introduce the phageome as a component of the gut microbiome and discuss fecal viral transplants and phage therapy in relation to cardiometabolic diseases. We then summarize the current state of phageome research in cardiometabolic diseases and propose how the phageome might indirectly influence cardiometabolic health through gut bacteria and their metabolites.
AB - Cardiometabolic diseases are leading causes of mortality in Western countries. Well-established risk factors include host genetics, lifestyle, diet, and the gut microbiome. Moreover, gut bacterial communities and their activities can be altered by bacteriophages (also known simply as phages), bacteria-infecting viruses, making these biological entities key regulators of human cardiometabolic health. The manipulation of bacterial populations by phages enables the possibility of using phages in the treatment of cardiometabolic diseases through phage therapy and fecal viral transplants. First, however, a deeper understanding of the role of the phageome in cardiometabolic diseases is required. In this review, we first introduce the phageome as a component of the gut microbiome and discuss fecal viral transplants and phage therapy in relation to cardiometabolic diseases. We then summarize the current state of phageome research in cardiometabolic diseases and propose how the phageome might indirectly influence cardiometabolic health through gut bacteria and their metabolites.
UR - http://www.scopus.com/inward/record.url?scp=85183999251&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2024.113728
DO - 10.1016/j.celrep.2024.113728
M3 - Review article
C2 - 38300802
SN - 2211-1247
VL - 43
SP - 113728
JO - Cell Reports
JF - Cell Reports
IS - 2
M1 - 113728
ER -